Get the Stockscreener App
0.5423
2.60%
-0.0145
After Hours:
.55
0.0077
+1.42%
Century Therapeutics Inc stock is traded at $0.5423, with a volume of 446.57K.
It is down -2.60% in the last 24 hours and up +10.25% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5568
Open:
$0.5579
24h Volume:
446.57K
Relative Volume:
0.61
Market Cap:
$46.85M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2368
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-4.64%
1M Performance:
+10.25%
6M Performance:
-0.26%
1Y Performance:
-65.46%
1-Day Range:
$0.54
$0.563
1-Week Range:
$0.5236
$0.59
52-Week Range:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5423 | 48.10M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Is Century Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Outlook & Reliable Trade Execution Plans - Trung tâm Dự báo KTTV quốc gia
Is Century Therapeutics Inc. building a consolidation baseJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
How to use a screener to detect Century Therapeutics Inc. breakoutsEarnings Summary Report & Daily Momentum Trading Reports - newser.com
Does Century Therapeutics Inc. show high probability of reboundJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
How to manage a losing position in Century Therapeutics Inc.Share Buyback & Consistent Income Trade Recommendations - newser.com
Century Therapeutics Inc. stock momentum explainedRisk Management & Consistent Income Trade Recommendations - newser.com
Is Century Therapeutics Inc. stock reversal real or fakeProduct Launch & Verified Momentum Stock Alerts - newser.com
Can Century Therapeutics Inc. recover in the next quarterMarket Activity Summary & Consistent Income Trade Recommendations - newser.com
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - GlobeNewswire
Century Therapeutics Inc. stock volume spike explainedTrade Analysis Report & Fast Momentum Entry Tips - newser.com
Is Century Therapeutics Inc. stock positioned well for digital economyPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
How Century Therapeutics Inc. stock trades before earningsWeekly Loss Report & Community Driven Trade Alerts - newser.com
Will Century Therapeutics Inc. rebound enough to break evenJuly 2025 Final Week & Proven Capital Preservation Tips - newser.com
Is now a turning point for Century Therapeutics Inc.July 2025 Opening Moves & High Conviction Buy Zone Alerts - newser.com
Applying chart zones and confluence areas to Century Therapeutics Inc.2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Yahoo Finance
Century Therapeutics (NASDAQ:IPSC) Upgraded by Wall Street Zen to Hold Rating - Defense World
Century Therapeutics Inc. stock outlook for YEARMarket Volume Report & Fast Exit/Entry Strategy Plans - newser.com
Does Century Therapeutics Inc. fit your quant trading modelJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
What the charts say about Century Therapeutics Inc. today2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - newser.com
Critical Analysis: Century Therapeutics (NASDAQ:IPSC) and TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
Layoff Tracker: Novo’s Cuts Leave Dozens of Manufacturing Workers Jobless - BioSpace
There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding - simplywall.st
How to escape a deep drawdown in Century Therapeutics Inc.July 2025 Update & Verified Momentum Stock Watchlist - newser.com
Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $3.75 - Defense World
Century Therapeutics Inc. recovery potential after sell offMarket Activity Recap & Risk Controlled Stock Pick Alerts - newser.com
How to build a dashboard for Century Therapeutics Inc. stockJobs Report & Community Consensus Trade Signals - newser.com
Is Century Therapeutics Inc. stock ready for a breakoutMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Why Century Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):